Skip to main content
Top
Published in: Drugs & Aging 11/2003

01-09-2003 | Original Research Article

Idiopathic Thrombocytopenic Purpura

A Retrospective Analysis in 139 Patients of the Influence of Age on the Response to Corticosteroids, Splenectomy and Danazol

Authors: Professor Emmanuel Andrès, Jacques Zimmer, Esther Noel, Georges Kaltenbach, Argyro Koumarianou, Dr Frédéric Maloisel

Published in: Drugs & Aging | Issue 11/2003

Login to get access

Abstract

Objective

To review the influence of age on the response of patients with idiopathic thrombocytopenic purpura (ITP) to corticosteroids, splenectomy and danazol.

Methods

We retrospectively reviewed a cohort of 139 consecutively treated patients with ITP diagnosed between 1985 and 1994. In particular, we analysed the therapies used, their response rates, prognostic indicators of response and adverse effects. Furthermore, we compared the efficacy and tolerability of the various therapies between younger and older patients (<60 and ≥60 years old).

Results

Corticosteroids were used as first-line treatment in 118 patients with an initial response rate of 83%. Age did not affect the outcome of corticosteroid therapy, but all the patients aged ≥60 years reported adverse effects. A splenectomy was performed in 55 patients with an initial response rate of 87%. Older patients had significantly poorer outcomes from splenectomy with higher postoperative morbidity. Finally, danazol was given in 33 patients with a favourable response in 72% of cases. Compared with younger patients, older patients had a significantly better outcome with danazol.

Conclusions

Age may have significant effects on the response to and adverse effects of therapy in ITP, and this should be considered when choosing the treatment modality for the elderly.
Literature
1.
2.
go back to reference Provan D, Newland A. Fifty years of idiopathic thrombocytopenic purpura (ITP): management of refractory ITP in adults. Br J Haematol 2002; 118: 933–44PubMedCrossRef Provan D, Newland A. Fifty years of idiopathic thrombocytopenic purpura (ITP): management of refractory ITP in adults. Br J Haematol 2002; 118: 933–44PubMedCrossRef
3.
go back to reference Semple JW. Immune pathophysiology of autoimmune thrombocytopenic purpura. Blood Rev 2002; 16: 9–12PubMedCrossRef Semple JW. Immune pathophysiology of autoimmune thrombocytopenic purpura. Blood Rev 2002; 16: 9–12PubMedCrossRef
5.
go back to reference George JN, Woolf SH. Raskob GE, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996; 88: 3–40PubMed George JN, Woolf SH. Raskob GE, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996; 88: 3–40PubMed
6.
go back to reference McMillan R. Classical management of refractory adult immune (idiopathic) thrombocytopenic purpura. Blood Rev 2002; 16: 51–5PubMedCrossRef McMillan R. Classical management of refractory adult immune (idiopathic) thrombocytopenic purpura. Blood Rev 2002; 16: 51–5PubMedCrossRef
7.
go back to reference Berchtold P, McMillan R. Therapy of chronic idiopathic thrombocytopenic purpura in adults. Blood 1989; 74: 2309–17PubMed Berchtold P, McMillan R. Therapy of chronic idiopathic thrombocytopenic purpura in adults. Blood 1989; 74: 2309–17PubMed
8.
go back to reference Kurata Y, Miyagawa S, Kosugi S, et al. High-titer antinuclear antibodies, anti-SSA/Ro antibodies and anti-nuclear RNP antibodies in patients with idiopathic thrombocytopenic purpura. Thromb Haemost 1994; 71: 184–7PubMed Kurata Y, Miyagawa S, Kosugi S, et al. High-titer antinuclear antibodies, anti-SSA/Ro antibodies and anti-nuclear RNP antibodies in patients with idiopathic thrombocytopenic purpura. Thromb Haemost 1994; 71: 184–7PubMed
9.
go back to reference Leung AY, Chim CS, Kwong YL, et al. Clinicopathologic and prognostic features of chronic idiopathic thrombocytopenic purpura in adult Chinese patients: an analysis of 220 cases. Ann Hematol 2001; 80: 384–6PubMedCrossRef Leung AY, Chim CS, Kwong YL, et al. Clinicopathologic and prognostic features of chronic idiopathic thrombocytopenic purpura in adult Chinese patients: an analysis of 220 cases. Ann Hematol 2001; 80: 384–6PubMedCrossRef
10.
go back to reference Pamuk GE, Pamuk ON, Baslar Z, et al. Overview of 321 patients with idiopathic thrombocytopenic purpura: retrospective analysis of the clinical features and response to therapy. Ann Hematol 2002; 81: 436–40PubMedCrossRef Pamuk GE, Pamuk ON, Baslar Z, et al. Overview of 321 patients with idiopathic thrombocytopenic purpura: retrospective analysis of the clinical features and response to therapy. Ann Hematol 2002; 81: 436–40PubMedCrossRef
11.
go back to reference Stasi R, Stipa E, Masi M, et al. Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura. Am J Med 1995; 98: 436–42PubMedCrossRef Stasi R, Stipa E, Masi M, et al. Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura. Am J Med 1995; 98: 436–42PubMedCrossRef
12.
go back to reference Difino SM, Lachant NA, Kirshner JJ, et al. Adult idiopathic thrombocytopenic purpura: clinical findings and response to therapy. Am J Med 1980; 69: 430–42PubMedCrossRef Difino SM, Lachant NA, Kirshner JJ, et al. Adult idiopathic thrombocytopenic purpura: clinical findings and response to therapy. Am J Med 1980; 69: 430–42PubMedCrossRef
13.
go back to reference Tobelem G, Chassang C, Asselain B, et al. Le purpura thrombopénique auto-immun: etude clinique et thérapeutique rétrospective de 544 observations. Nouv Presse Med 1981; 10: 2871–5PubMed Tobelem G, Chassang C, Asselain B, et al. Le purpura thrombopénique auto-immun: etude clinique et thérapeutique rétrospective de 544 observations. Nouv Presse Med 1981; 10: 2871–5PubMed
14.
go back to reference den Ottolander GJ, Gratama JW, de Koning J, et al. Long-term follow-up study of 168 patients with immune thrombocytopenia. Scand J Haematol 1984; 32: 101–10CrossRef den Ottolander GJ, Gratama JW, de Koning J, et al. Long-term follow-up study of 168 patients with immune thrombocytopenia. Scand J Haematol 1984; 32: 101–10CrossRef
15.
go back to reference Ahn YS, Harrington WJ, Simon SR, et al. Danazol for the treatment of idiopathic thrombocytopenic purpura. N Engl J Med 1983; 308: 1396–9PubMedCrossRef Ahn YS, Harrington WJ, Simon SR, et al. Danazol for the treatment of idiopathic thrombocytopenic purpura. N Engl J Med 1983; 308: 1396–9PubMedCrossRef
16.
go back to reference Ahn YS, Mylvaganam R, Garcia RO, et al. Low-dose danazol therapy in idiopathic thrombocytopenic purpura. Ann Intern Med 1987; 107: 177–81PubMed Ahn YS, Mylvaganam R, Garcia RO, et al. Low-dose danazol therapy in idiopathic thrombocytopenic purpura. Ann Intern Med 1987; 107: 177–81PubMed
17.
go back to reference Ahn YS, Rocha R, Mylvaganam R, et al. Long-term danazol therapy in autoimmune thrombocytopenia: unmaintained remission and age-dependent response in women. Ann Intern Med 1989; 111:723–9PubMed Ahn YS, Rocha R, Mylvaganam R, et al. Long-term danazol therapy in autoimmune thrombocytopenia: unmaintained remission and age-dependent response in women. Ann Intern Med 1989; 111:723–9PubMed
18.
19.
go back to reference Nalli G, Sajeva MR, Maffé GC, et al. Danazol therapy for idiopathic thrombocytopenic purpura. Haematologica 1988; 73: 55–7PubMed Nalli G, Sajeva MR, Maffé GC, et al. Danazol therapy for idiopathic thrombocytopenic purpura. Haematologica 1988; 73: 55–7PubMed
20.
go back to reference Mazzucconi MG, Francesconi M, Falcione E, et al. Danazol therapy in refractory chronic immune thrombocytopenic purpura. Acta Haematol 1987; 77: 45–7PubMedCrossRef Mazzucconi MG, Francesconi M, Falcione E, et al. Danazol therapy in refractory chronic immune thrombocytopenic purpura. Acta Haematol 1987; 77: 45–7PubMedCrossRef
21.
go back to reference McVerry BA, Auger M, Bellingham AJ. The use of danazol in the management of chronic immune thrombocytopenic purpura. Br J Haematol 1985; 61: 145–8PubMedCrossRef McVerry BA, Auger M, Bellingham AJ. The use of danazol in the management of chronic immune thrombocytopenic purpura. Br J Haematol 1985; 61: 145–8PubMedCrossRef
22.
go back to reference Shashaty GG, Rath CE. Idiopathic thrombocytopenic purpura in elderly. Am J Med Sci 1978; 276: 263–7PubMedCrossRef Shashaty GG, Rath CE. Idiopathic thrombocytopenic purpura in elderly. Am J Med Sci 1978; 276: 263–7PubMedCrossRef
23.
go back to reference Taillan B, Hastier A, Ferrari E, et al. Purpura thrombopénique chronique chez le sujet. Nouv Presse Med 1991; 34: 1651–4 Taillan B, Hastier A, Ferrari E, et al. Purpura thrombopénique chronique chez le sujet. Nouv Presse Med 1991; 34: 1651–4
24.
go back to reference Linares M, Cervero A, Colomina P, et al. Purpura thrombopénique chronique du sujet. Nouv Presse Med 1995; 93: 80–2 Linares M, Cervero A, Colomina P, et al. Purpura thrombopénique chronique du sujet. Nouv Presse Med 1995; 93: 80–2
25.
go back to reference Cortelazzo S, Finazzi G, Buelli M, et al. High risk of severe bleeding in aged patients with chronic idiopathic thrombocytopenic purpura. Blood 1991; 77: 31–3PubMed Cortelazzo S, Finazzi G, Buelli M, et al. High risk of severe bleeding in aged patients with chronic idiopathic thrombocytopenic purpura. Blood 1991; 77: 31–3PubMed
Metadata
Title
Idiopathic Thrombocytopenic Purpura
A Retrospective Analysis in 139 Patients of the Influence of Age on the Response to Corticosteroids, Splenectomy and Danazol
Authors
Professor Emmanuel Andrès
Jacques Zimmer
Esther Noel
Georges Kaltenbach
Argyro Koumarianou
Dr Frédéric Maloisel
Publication date
01-09-2003
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 11/2003
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.2165/00002512-200320110-00005

Other articles of this Issue 11/2003

Drugs & Aging 11/2003 Go to the issue

Adis Drug Profile

Transdermal Oxybutynin

Adis Drug Profile

Transdermal Oxybutynin

Adis Drug Profile

Transdermal Oxybutynin

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.